Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Biological Therapy in Treating Patients With Glioblastoma Multiforme

Study:

Adoptive Immunotherapy of Glioblastoma Multiforme With Tumor-Sensitized, Ex Vivo Activated T Lymphocytes

Rationale:

Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.

Purpose:

Phase II trial to study the effectiveness of biological therapy in treating patients with glioblastoma multiforme.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Brain and Central Nervous System Tumors Biological: autologous tumor cell vaccine
Biological: sargramostim
Biological: tumor-draining lymph node lymphocyte therapy
Drug: cyclophosphamide
Procedure: conventional surgery
Phase 2

Verified by The Cleveland Clinic December, 2008

Sponsored by: The Cleveland Clinic
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00003185

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Suyu Shu, PhD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site